FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC

Episode
292
Soundcloud
Share

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of telisotuzumab vedotin, an antibody-drug conjugate, for NSCLC with high c-MET expression. Dr. Mor Moskovitz and Dr. Jonathan Goldman joined the conversation to help review the data and offer perspective on this new agent.

Guest
Stephen Liu
Stephen Liu

MD

Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Jonathan Goldman
Jonathan Goldman

MD

Professor of Medicine, Director of Clinical Trials in Thoracic Oncology & Associate Director of Drug Development
UCLA Hematology & Oncology
Mor Moskovitz
Mor Moskovitz

MD

Head of Thoracic Oncology Service
Davidoff Cancer Center
Beilinson Medical Center

Other Podcast